Article

Stem Cells Could Improve Stroke Recovery, Study Finds

Author(s):

The use of preconditioned mesenchymal stem cells (MSCs) may offer a new, safer alternative to other cellular therapies used for tissue regeneration, according to recent study.

The use of preconditioned mesenchymal stem cells (MSCs) may offer a new, safer alternative to other cellular therapies used for tissue regeneration, according to recent study.

The study, conducted by Ji Yong Lee, of the Institute for BioMedical Convergences at the Catholic Kwandong University-International St. Mary’s Hospital in the Republic of Korea, and colleagues is described in an article published in the journal Nature on September 9, 2016.

Previous research has demonstrated the beneficial therapeutic possibilities of cell transplantation for patients with a variety of central nervous system conditions, including those with ischemic stroke. The authors say, “We and other groups have shown that in animal models MSCs can improve functional deficits induced by ischemic stroke,” adding, “therapeutic benefits are evident within days of cellular injection.”

“Recent studies on MSCs have shown that the secretome, exosome, and microvesicle (MV) fractions of conditioned media mimic the beneficial effects of MSCs,” say the authors. In the recent study they say they investigated “whether MSC-MVs and MVs isolated from MSCs treated with normal (NBE-MSC-MVs) and stroke (SBE-MSC-MVs) rat brain extract would improve functional recovery and tissue regeneration” in a rat model of stroke.

The results of the study showed that in both normal and stroke-injured brains had improved neurological outcomes as a result of treatment. The researchers say, “the results of this study clearly support the hypothesis that MSC transplantation or injection promotes endogenous neurogenesis and improves behavioral deficits after ischemic stroke.”

The researchers conclude by noting that “a number of clinical trials of stem cell transplantation for neurodegenerative diseases such as stroke are underway, and an impressive body of evidence documenting the clinical benefits of such approaches is accumulating, newly introduced approaches utilizing MVs/exosomes derived from MSCs represent a novel and safe alternative.”

Further Coverage:

Stem Cell Treatment Seen for MS

New Technology Looks to Improve Treatment of Neurodegenerative Diseases

Stem Cell Therapy for Myasthenia Gravis

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
© 2024 MJH Life Sciences

All rights reserved.